Search

Your search keyword '"Wolinsky, J.S."' showing total 37 results
Start Over Author "Wolinsky, J.S."
37 results on '"Wolinsky, J.S."'

8. P61 Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial

Author

Wolinsky, J.S., primary, Hartung, H.P., additional, Brochet, B., additional, Montalban, X., additional, Naismith, R.T., additional, Manfrini, M., additional, Garas, M., additional, Model, F., additional, Hubeaux, S., additional, Kappos, L., additional, and Hauser, S.L., additional

Published
2019
Full Text
View/download PDF

11. Sustained Reduction in Confirmed Disability Progression in Patients with Primary Progressive Multiple Sclerosis Treated with Ocrelizumab in the Open-label Extension Period of the Phase III ORATORIO trial

Author

Hauser, S.L., primary, Wolinsky, J.S., additional, Brochet, B., additional, Montalban, X., additional, Naismith, R.T., additional, Manfrini, M., additional, Garas, M., additional, Villoslada, P., additional, Model, F., additional, Hubeaux, S., additional, and Kappos, L., additional

Published
2018
Full Text
View/download PDF

12. Long-term Reduction in Brain MRI Disease Activity and Atrophy after 5 years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis

Author

Arnold, D.L., primary, Kappos, L., additional, Hauser, S.L., additional, Montalban, X., additional, Traboulsee, A., additional, Wolinsky, J.S., additional, Manfrini, M., additional, Levesque, V., additional, Villoslada, P., additional, Belachew, S., additional, Model, F., additional, Hubeaux, S., additional, and Bar-Or, A., additional

Published
2018
Full Text
View/download PDF

13. P 1 Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis – analysis of the phase III, double-blind, double-dummy, interferon beta-1a- controlled OPERA I and OPERA II studies

Author

Ziemssen, T., primary, Arnold, D.L., additional, Bar-Or, A., additional, Comi, G., additional, Hartung, H.P., additional, Hauser, S.L., additional, Kappos, L., additional, Lublin, F., additional, Selmaj, K., additional, Traboulsee, A., additional, Masterman, D., additional, Chin, P., additional, Garren, H., additional, and Wolinsky, J.S., additional

Published
2017
Full Text
View/download PDF

26. Grey matter abnormalities in multiple sclerosis: proton magnetic resonance spectroscopic imaging.

Author

Sharma, R., Narayana, P.A., and Wolinsky, J.S.

Subjects
PROTON magnetic resonance spectroscopy, MULTIPLE sclerosis, SPECTRUM analysis
Abstract

Pathologically defined abnormalities in the cortical gray matter (GM) are well described in multiple sclerosis (MS) but are infrequently seen by conventional magnetic resonance imaging (MRI). We systematically evaluated 52 relapsing – remitting MS patients and 20 normal volunteers with high resolution MRI and short echo proton magnetic resonance spectroscopic imaging (MRSI). Individual tissue contributions to the spectroscopic voxels were estimated based on MRI that incorporated both CSF suppression and magnetization transfer, or double inversion images in which both CSF and GM were suppressed. Strong resonances in the 0.8 to 1.5 p.p.m. spectral region were observed in 13 MS patients. Image segmentation based on the MRI characteristics of tissues contributing to the spectroscopic voxels showed that these additional peaks originated mainly from GM. The presence of these additional peaks suggests that the normal appearance GM on MRI, is biochemically abnormal in a substantial proportion of relapsing – remitting MS patients. [ABSTRACT FROM AUTHOR]

Published
2001
Full Text
View/download PDF

27. Teriflunomide added to interferon- in relapsing multiple sclerosis

Author

Freedman, M.S., Wolinsky, J.S., Wamil, B., Confavreux, C., Comi, G., Kappos, L., Olsson, T.P., Miller, A., Benzerdjeb, H., Li, H., Simonson, C., and O'Connor, P.W.

Abstract

To evaluate teriflunomide as add-on therapy to ongoing stable-dosed interferon- (IFN) in patients with relapsing forms of multiple sclerosis (RMS).

Published
2012
Full Text
View/download PDF

28. Interferon -1b and glatiramer acetate effects on permanent black hole evolution(LOE Classification)

Author

Filippi, M., Rocca, M.A., Camesasca, F., Cook, S., O'Connor, P., Arnason, B.G.W., Kappos, L., Goodin, D., Jeffery, D., Hartung, H.-P., Comi, G., Wolinsky, J.S., Bogumil, T., Pohl, C., Beckmann, K., Sandbrink, R., Croze, E., Brown, C., DeSimone, T.M., Arnold, D.L., Cutter, G., and Knappertz, V.

Abstract

To compare interferon -1b (IFN-1b) and glatiramer acetate (GA) on new lesion (NL) (gadolinium-enhancing, new T2) evolution into permanent black holes (PBH)—a marker of irreversible tissue damage—in patients with relapsing-remitting multiple sclerosis (RRMS).

Published
2011
Full Text
View/download PDF

29. Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis

Author

Sormani, M.P., Rovaris, M., Valsasina, P., Wolinsky, J.S., Comi, G., and Filippi, M.

Abstract

The measurement errors associated with two techniques for brain atrophy assessment in multiple sclerosis (MS) were estimated. The measurement error of a semiautomated, nonnormalized technique with partial brain coverage was about twofold higher than that of a fully automated, normalized technique with full brain coverage (Structural Image Evaluation of Normalized Atrophy software SIENA). As shown by the analysis of data from a clinical trial of glatiramer acetate, the use of SIENA increases the study power to detect a treatment effect on brain volume changes in MS patients.

Published
2004

34. Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry

Author

Montalban, Xavier, Butzkueven, Helmut, Spelman, Tim, Horakova, Dana, Hughes, Stella, Solaro, Claudio Marcello, Izquierdo, Guillermo, Kubala Havrdova, Eva, Grand'Maison, Francois, Prat, Alexandre, Girard, Marc, Hupperts, Raymond, Onofrj, Marco, Lugaresi, Alessandra, Taylor, Bruce, Giovannoni, Gavin, Kappos, Ludwig, Hauser, Stephen L., Craveiro, Licinio, Freitas, Rita, Model, Fabian, Overell, James, Muros-Le Rouzic, Erwan, Sauter, Annette, Wang, Qing, Wormser, David, Wolinsky, Jerry S., MSBase Study Group, Universitat Autònoma de Barcelona, Butzkueven H., Spelman T., Horakova D., Hughes S., Solaro C., Izquierdo G., Kubala Havrdova E., Grand'Maison F., Prat A., Girard M., Hupperts R., Onofrj M., Lugaresi A., Taylor B., Giovannoni G., Kappos L., Hauser S.L., Montalban X., Craveiro L., Freitas R., Model F., Overell J., Muros-Le Rouzic E., Sauter A., Wang Q., Wormser D., and Wolinsky J.S.

Subjects
medicine.medical_specialty, Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Placebo, Placebo group, 03 medical and health sciences, Primary progressive multiple sclerosis, 0302 clinical medicine, Wheelchair, ocrelizumab, wheelchair, Internal medicine, Medicine, Humans, Ocrelizumab, 030212 general & internal medicine, Registries, Disease progression, Expanded Disability Status Scale, business.industry, Multiple Sclerosis, Chronic Progressive, primary progressive multiple sclerosi, Confidence interval, Neurology, Wheelchairs, Cohort, Disease Progression, Neurology (clinical), business, 030217 neurology & neurosurgery, medicine.drug
Abstract

Background and purpose: Reaching Expanded Disability Status Scale (EDSS) ≥7.0 represents the requirement for a wheelchair. Here we (i) assess the effect of ocrelizumab on time to EDSS ≥7.0 over the ORATORIO (NCT01194570) double-blind and extended controlled periods (DBP+ECP), (ii) quantify likely long-term benefits by extrapolating results, and (iii) assess the plausibility of extrapolations using an independent real-world cohort (MSBase registry; ACTRN12605000455662). Methods: Post hoc analyses assessing time to 24-week confirmed EDSS ≥7.0 in two cohorts of patients with primary progressive multiple sclerosis (baseline EDSS 3.0–6.5) were investigated in ORATORIO and MSBase. Results: In the ORATORIO DBP+ECP, ocrelizumab reduced the risk of 24-week confirmed EDSS ≥7.0 (hazard ratio=0.54, 95% confidence interval [CI]: 0.31–0.92; p=0.022). Extrapolated median time to 24-week confirmed EDSS ≥7.0 was 12.1 and 19.2years for placebo and ocrelizumab, respectively (7.1-year delay [95% CI: −4.3 to 18.4]). In MSBase, the median time to 24-week confirmed EDSS ≥7.0 was 12.4years. Conclusions: Compared with placebo, ocrelizumab significantly delayed time to 24-week confirmed wheelchair requirement in ORATORIO. The plausibility of the extrapolated median time to reach this milestone in the placebo group was supported by observed real-world data from MSBase. Extrapolated benefits for ocrelizumab over placebo could represent a truly meaningful delay in loss of ambulation and independence.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results